Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 22-00 

Low-dose cytotoxics as "anti-angiogenesis treatment" following adjuvant induction chemotherapy for patients with ER-negative and PgR-negative breast cancer

DESIGN

Please click on the picture to see a larger version

Serum Substudy


Assessment of Vascular Endothelial Growth Factor (VEGF), Soluble Her2 Protein (NRP, Neu-Related Protein), and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in serum samples.


Study Chair
Dr. Marco Colleoni - Milano, Italy

Statistician
Shari Gelber

Trial Coordinators
Holly Shaw, Renaye Hecker

Data Managers
Joie Celano, Sandra Lippert,


IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg22@fstrf.org

Date of Activation
November 22, 2000

Targeted Accrual
900 patients


Substudies Serum Substudy



News

18.12.2014:
New publications are available 

11.12.2014:
San Antonio Breast Cancer Symposium 2014: IBCSG Presents SOFT Results.

10.12.2014:
IBCSG and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast

All News

 
  Print